Individuals with filaggrin-related eczema and asthma have increased long-term medication and hospital admission costs.

Br J Dermatol 2018 Sep 31;179(3):717-723. Epub 2018 May 31.

Academic Department of Paediatrics, Brighton & Sussex Medical School, Royal Alexandra Children's Hospital, Brighton, U.K.

Background: Eczema and asthma are chronic diseases with onset usually before the age of 5 years. More than 50% of individuals with eczema will develop asthma and/or other allergic diseases. Several loss-of-function mutations in filaggrin (FLG) have been identified in patients with eczema. However, the association of FLG with healthcare use is unknown.

Objectives: To determine whether FLG mutations are associated with increased prescribing for eczema and asthma and whether increased prescribing is associated with increased healthcare costs.

Methods: A secondary analysis of BREATHE, a cross-sectional study of gene-environment associations with asthma severity, was undertaken. BREATHE data was collected for 1100 participants with asthma, in Tayside and Fife, Scotland during the period 2003-2005. Through collaboration with the Health Informatics Centre in Dundee, BREATHE was linked to accident and emergency, community prescribing and Scottish morbidity records. The data linkage allowed longitudinal exploration of associations between genetic variation and prescribing.

Results: An association was found between FLG mutations and increased prescribing for mild and moderate eczema, asthma-reliever medicine and asthma exacerbations. A strong association was found between FLG mutations and prescribing of emollients [incidence rate ratio (IRR) 2·19, 95% confidence interval (CI) 1·36-3·52], treatment for severe eczema (IRR 2·18, 95% CI 1·22-3·91) and a combination of a long-acting β -agonist and corticosteroids (IRR 3·29, 95% CI 1·68-6·43).

Conclusions: The presence of FLG mutations in this cohort is associated with increased prescribing for eczema and asthma. Randomized controlled trials are required to determine if these individuals could benefit from management strategies to reduce morbidity and treatment costs.

Abstract Video

Increased medication costs for filaggrin-related eczema and asthma, P. Soares et al


Source: British Journal of Dermatology

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.16720DOI Listing

Still can't find the full text of the article?

We can help you send a request to the authors directly.
September 2018
342 Reads

Article Mentions


Provided by Crossref Event Data
twitter
Twitter: Shef_Derm
September 26, 2018, 7:30 am EST
twitter
Twitter: BrJDermatol
September 26, 2018, 7:15 am EST
twitter
Twitter: BioxS
June 8, 2018, 6:40 am EST
twitter
Twitter: BSFcharity
June 6, 2018, 9:00 am EST

Publication Analysis

Top Keywords

flg mutations
16
eczema asthma
16
increased prescribing
16
association flg
12
associated increased
12
asthma
8
eczema
8
asthma increased
8
prescribing eczema
8
prescribing
6
flg
6
increased
6
mutations
5
long-acting -agonist
4
gene-environment associations
4
period 2003-2005
4
collaboration health
4
2003-2005 collaboration
4
informatics centre
4
breathe linked
4

References

(Supplied by CrossRef)

Scottish Intercollegiate Guidelines Network et al.
2011
Atopic dermatitis
Bieber et al.
N Engl J Med 2008

Scottish Intercollegiate Guidelines Network and British Thoracic Society et al.
2016
The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma
Bantz et al.
J Clin Cell Immunol 2014

Similar Publications